by Sharon O’Reilly
For more than half a century, total joint replacement (TJR) has enabled millions of Americans with debilitating arthritic hips and...
With few new treatment options on the horizon for patients suffering from joint pain associated with hip and knee osteoarthritis, it should come as no surprise that the business of joint replacement is booming and will continue to do so for the foreseeable future. Even in the current economic environment where elective joint replacement procedures are likely to slow down, there has not (yet) been a significant impact on implant sales.The industry admits it is not immune to the global economic crisis, at least in the short term. However, over the long haul, the general consensus is that this market will remain strong owing to solid growth in the patient pool.
by Sharon O’Reilly
For more than half a century, total joint replacement (TJR) has enabled millions of Americans with debilitating arthritic hips and...
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.
Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.
Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.